What does a serum vitamin B12 level of 210 pg/mL indicate and how should it be treated?

A serum vitamin B12 level of 210 pg/mL falls in the indeterminate range and requires confirmatory testing with methylmalonic acid (MMA) before making treatment decisions.

Your patient's B12 level of 210 pg/mL (155 pmol/L) sits in the "possible deficiency" zone where you cannot confirm or exclude deficiency based on this result alone 1. According to the 2024 NICE guidelines, levels between 180-350 pg/mL (133-258 pmol/L) are indeterminate and warrant further metabolic testing 1.

Immediate Next Steps

Order a serum methylmalonic acid (MMA) level to determine if functional B12 deficiency exists 1, 2. This is the recommended confirmatory test when total B12 falls in the indeterminate range. An elevated MMA (>280 nmol/L in young patients with normal renal function, or >0.4 nmol/L per other references) confirms true B12 deficiency 2, 3.

Alternatively, you can measure homocysteine (>20 µmol/L suggests deficiency in folate-replete patients), though MMA is more specific for B12 deficiency 2, 3.

Clinical Assessment While Awaiting MMA Results

Look specifically for these manifestations that would indicate treatment urgency:

Neurological red flags (these can become irreversible if untreated):

• Peripheral neuropathy: pins and needles, numbness, impaired proprioception
• Myelopathy: balance issues, falls, sensory ataxia, impaired gait
• Cognitive symptoms: "brain fog," memory loss, concentration difficulties
• Visual problems: blurred vision, optic atrophy, scotomas 1

Hematological findings:

• Macrocytic anemia
• Unexplained fatigue 1

Identify the Underlying Cause

Assess for these common risk factors 1:

Dietary:

• Vegan/vegetarian diet without B12 supplementation
• Food insecurity or inability to prepare meals

Malabsorption:

• Atrophic gastritis (test for H. pylori and anti-parietal cell/intrinsic factor antibodies if no clear cause) 2
• Celiac disease
• Prior gastric surgery

Medications:

• Metformin (very common culprit)
• Proton pump inhibitors or H2 blockers
• Colchicine, phenobarbital, pregabalin, primidone 1

Other conditions:

• Autoimmune diseases (thyroid disease, type 1 diabetes, Sjögren syndrome)
• Family history of B12 deficiency or autoimmune conditions 1

Treatment Algorithm

If MMA is Elevated (Confirming Deficiency):

For patients WITH neurological symptoms or severe manifestations:

• Start intramuscular B12 immediately (1000 mcg IM) 2, 4
• Do not wait for MMA results if neurological symptoms are present—the risk of irreversible damage outweighs the risk of unnecessary treatment
• Continue parenteral therapy initially, then transition based on cause 4

For patients WITHOUT neurological symptoms:

• Oral high-dose B12 (1000-2000 mcg daily) is equally effective as intramuscular administration 2, 5, 6
• This applies regardless of the cause of deficiency (absorption of high-dose oral B12 occurs via passive diffusion, bypassing intrinsic factor) 5

If MMA is Normal:

The patient does not have functional B12 deficiency despite the borderline serum level. Consider:

• Reassurance if asymptomatic
• Dietary counseling if intake is suboptimal
• Recheck in 3-6 months if risk factors persist

Common Pitfalls to Avoid

1. Don't delay treatment if neurological symptoms are present—neurological damage can become permanent. Start treatment empirically while awaiting confirmatory tests 2, 4.

2. Don't assume low-normal B12 levels exclude deficiency—up to 50% of patients with metabolic evidence of deficiency have B12 levels in the "normal" range 3. This is why your patient's 210 pg/mL level requires MMA testing.

3. Don't forget to check renal function before interpreting MMA—MMA is elevated in renal insufficiency independent of B12 status 3.

4. Don't overlook folate status—ensure folate is adequate before interpreting homocysteine, as both B12 and folate deficiency elevate homocysteine 3.

5. Don't use serum B12 alone for diagnosis in the 180-350 pg/mL range—this is explicitly an indeterminate zone requiring metabolic confirmation 1.

The 2024 NICE guidelines emphasize that clinical symptoms should receive highest priority in diagnosis 4, so if your patient has suggestive symptoms (especially neurological), err on the side of treatment while awaiting confirmatory testing.